MCID: DXR001
MIFTS: 32

Doxorubicin Induced Cardiomyopathy

Categories: Cardiovascular diseases, Rare diseases

Aliases & Classifications for Doxorubicin Induced Cardiomyopathy

MalaCards integrated aliases for Doxorubicin Induced Cardiomyopathy:

Name: Doxorubicin Induced Cardiomyopathy 20

Classifications:



Summaries for Doxorubicin Induced Cardiomyopathy

MalaCards based summary : Doxorubicin Induced Cardiomyopathy is related to soft tissue sarcoma and dilated cardiomyopathy. An important gene associated with Doxorubicin Induced Cardiomyopathy is GATA4 (GATA Binding Protein 4), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Doxorubicin and Liposomal doxorubicin have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, bone and endothelial, and related phenotypes are Decreased cell migration and Decreased cell migration

Related Diseases for Doxorubicin Induced Cardiomyopathy

Diseases related to Doxorubicin Induced Cardiomyopathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 48)
# Related Disease Score Top Affiliating Genes
1 soft tissue sarcoma 30.3 EGFR CSF3
2 dilated cardiomyopathy 29.4 MAPK14 HGF GATA4 EGFR DES CSF3
3 atrial standstill 1 11.1
4 congestive heart failure 10.4
5 osteogenic sarcoma 10.2
6 chronic erosive gastritis 10.1 MET HGF
7 heart disease 10.1
8 myocarditis 10.1
9 pediatric hepatocellular carcinoma 10.1 MET HGF
10 familial renal papillary carcinoma 10.1 MET HGF
11 deafness, autosomal recessive 97 10.1 MET HGF
12 papillary thyroid microcarcinoma 10.0 MET HGF
13 poems syndrome 10.0 HGF CSF3
14 large cell medulloblastoma 10.0 MET HGF
15 hereditary renal cell carcinoma 10.0 MET HGF
16 biliary tract cancer 10.0 MET EGFR
17 spinal chordoma 10.0 MET EGFR
18 proteasome-associated autoinflammatory syndrome 1 9.9
19 insulin-like growth factor i 9.9
20 cardiac arrest 9.9
21 sarcoma 9.9
22 pertussis 9.9
23 nephrotic syndrome 9.9
24 cardiovascular system disease 9.9
25 lipid metabolism disorder 9.9
26 hyperglycemia 9.9
27 spindle cell sarcoma 9.9
28 fibrosarcomatous osteosarcoma 9.9
29 periodontitis 9.9
30 mitochondrial disorders 9.9
31 inguinal hernia 9.9 MET HGF GATA4
32 hypopharynx cancer 9.9 MET EGFR
33 sarcoma, synovial 9.9 MET HGF DES
34 mucositis 9.9 MET HGF CSF3
35 gastroesophageal adenocarcinoma 9.9 MET EGFR
36 alveolar soft part sarcoma 9.9 MET EGFR DES
37 chordoma 9.9 MET EGFR DES
38 salivary gland carcinoma 9.8 MET HGF EGFR
39 renal cell carcinoma, papillary, 1 9.8 MET HGF EGFR
40 pulmonary blastoma 9.8 EGFR DES
41 melanoma, uveal 9.7 MET HGF EGFR
42 myeloproliferative neoplasm 9.7 EPOR EGFR CSF3
43 pancreatic adenocarcinoma 9.6 MET HGF EGFR
44 medulloblastoma 9.5 MET HGF EGFR DES CSF3
45 cholangiocarcinoma 9.4 MET MAPK14 HGF EGFR
46 myocardial infarction 9.4 MAPK14 HGF GATA4 CSF3 CNR1
47 leukemia, chronic myeloid 9.3 MAPK14 EPOR EGFR CSF3
48 disease of mental health 8.9 MAPK14 GATA4 EPHB2 EGFR CSF3 CNR1

Graphical network of the top 20 diseases related to Doxorubicin Induced Cardiomyopathy:



Diseases related to Doxorubicin Induced Cardiomyopathy

Symptoms & Phenotypes for Doxorubicin Induced Cardiomyopathy

GenomeRNAi Phenotypes related to Doxorubicin Induced Cardiomyopathy according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased cell migration GR00055-A-1 9.33 EPHB2 MET
2 Decreased cell migration GR00055-A-3 9.33 EGFR
3 Decreased substrate adherent cell growth GR00193-A-2 9.13 EGFR EPHB2 MAPK14
4 Decreased viability after Chlamydia trachomatis serovar L2 infection and TNF-alpha/CHX stimulation GR00206-A 8.62 MAPK14 MET

MGI Mouse Phenotypes related to Doxorubicin Induced Cardiomyopathy:

46 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.15 CNR1 DES EGFR EPHB2 EPOR GATA4
2 cardiovascular system MP:0005385 10.11 DES ECE1 EGFR EPOR GATA4 HGF
3 growth/size/body region MP:0005378 10.09 CNR1 ECE1 EGFR EPHB2 EPOR GATA4
4 embryo MP:0005380 10.06 CNR1 ECE1 EGFR EPOR GATA4 HGF
5 mortality/aging MP:0010768 10.02 CNR1 DES ECE1 EGFR EPHB2 EPOR
6 hematopoietic system MP:0005397 10.01 CSF3 ECE1 EGFR EPHB2 EPOR GATA4
7 digestive/alimentary MP:0005381 9.95 CNR1 ECE1 EGFR EPHB2 GATA4 MET
8 liver/biliary system MP:0005370 9.85 EGFR EPOR GATA4 HGF MAPK14 MET
9 nervous system MP:0003631 9.81 CNR1 ECE1 EGFR EPHB2 EPOR GATA4
10 muscle MP:0005369 9.73 DES ECE1 EGFR GATA4 MAPK14 MET
11 no phenotypic analysis MP:0003012 9.43 CNR1 EGFR EPOR GATA4 HGF MET
12 normal MP:0002873 9.17 CNR1 ECE1 EGFR EPOR GATA4 MAPK14

Drugs & Therapeutics for Doxorubicin Induced Cardiomyopathy

Drugs for Doxorubicin Induced Cardiomyopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):


# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational 23214-92-8 31703
2
Liposomal doxorubicin 31703

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Prevention Using Exercise Rehabilitation to Offset Cardiac Toxicities Induced Via Chemotherapy Completed NCT02796365
2 The Role of suPAR in Doxorubicin Induced Cardiomyopathy in Breast Cancer Patients: Causative vs. Predictor Active, not recruiting NCT03505164

Search NIH Clinical Center for Doxorubicin Induced Cardiomyopathy

Genetic Tests for Doxorubicin Induced Cardiomyopathy

Anatomical Context for Doxorubicin Induced Cardiomyopathy

MalaCards organs/tissues related to Doxorubicin Induced Cardiomyopathy:

40
Bone Marrow, Bone, Endothelial, Myeloid, Pituitary

Publications for Doxorubicin Induced Cardiomyopathy

Articles related to Doxorubicin Induced Cardiomyopathy:

(show top 50) (show all 295)
# Title Authors PMID Year
1
Klotho attenuated Doxorubicin-induced cardiomyopathy by alleviating Dynamin-related protein 1 - mediated mitochondrial dysfunction. 61
33539906 2021
2
Genetic variants associated with therapy-related cardiomyopathy among childhood cancer survivors of African ancestry. 61
33288658 2020
3
Prophylactic, single-drug cardioprotection in a comparative, experimental study of doxorubicin-induced cardiomyopathy. 61
33298102 2020
4
Features of Myocardial Remodeling and Changes in the Blood Lipid Spectrum in Experimental Doxorubicin-Induced Cardiomyopathy and Atorvastatin Administration. 61
33222079 2020
5
Anthracycline Cardiotoxicity in a Patient with Diffuse Large B-Cell Lymphoma: A Case Report. 61
33214965 2020
6
TLR9 Binding to Beclin 1 and Mitochondrial SIRT3 by a Sodium-Glucose Co-Transporter 2 Inhibitor Protects the Heart from Doxorubicin Toxicity. 61
33138323 2020
7
Cardioprotective effect of grape polyphenol extract against doxorubicin induced cardiotoxicity. 61
32895481 2020
8
[Prevention of Diastolic Dysfunction Caused by Doxorubicin by Mitochondrial Antioxidant Plastomitin]. 61
33155947 2020
9
Bisoprolol and linagliptin ameliorated electrical and mechanical isometric myocardial contractions in doxorubicin-induced cardiomyopathy in rats. 61
32048248 2020
10
Self-Maintenance of Cardiac Resident Reparative Macrophages Attenuates Doxorubicin-Induced Cardiomyopathy Through the SR-A1-c-Myc Axis. 61
32466726 2020
11
Antioxidant, antiapoptotic, and antifibrotic effects of the combination of liposomal resveratrol and carvedilol against doxorubicin-induced cardiomyopathy in rats. 61
32173980 2020
12
Cyp1 Inhibition Prevents Doxorubicin-Induced Cardiomyopathy in a Zebrafish Heart-Failure Model. 61
32003101 2020
13
The Tumor-Suppressive Human Circular RNA CircITCH Sponges miR-330-5p to Ameliorate Doxorubicin-Induced Cardiotoxicity Through Upregulating SIRT6, Survivin, and SERCA2a. 61
32392088 2020
14
Comparison of exercise training and estrogen supplementation on mast cell-mediated doxorubicin-induced cardiotoxicity. 61
32159365 2020
15
Mitochondria-dependent ferroptosis plays a pivotal role in doxorubicin cardiotoxicity. 61
32376803 2020
16
Empagliflozin prevents doxorubicin-induced myocardial dysfunction. 61
32414364 2020
17
A small-molecule allosteric inhibitor of BAX protects against doxorubicin-induced cardiomyopathy. 61
32776015 2020
18
Mitochondrial Determinants of Doxorubicin-Induced Cardiomyopathy. 61
32213135 2020
19
Follistatin-Like 1 Protects against Doxorubicin-Induced Cardiomyopathy through Upregulation of Nrf2. 61
32831995 2020
20
Histone Demethylase JMJD3 Mediated Doxorubicin-Induced Cardiomyopathy by Suppressing SESN2 Expression. 61
33117796 2020
21
Protective role of p53 in doxorubicin-induced cardiomyopathy as a mitochondrial disease. 61
32391420 2020
22
MiR-124 attenuates doxorubicin-induced cardiac injury via inhibiting p66Shc-mediated oxidative stress. 61
31672275 2020
23
A Novel Long-circulating DOX Liposome: Formulation and Pharmacokinetics Studies. 61
32787769 2020
24
Therapeutic Effects of Liraglutide, Oxytocin and Granulocyte Colony-Stimulating Factor in Doxorubicin-Induced Cardiomyopathy Model: An Experimental Animal Study. 61
31054117 2019
25
Effect of ghrelin on VEGF-B and connexin-43 in a rat model of doxorubicin-induced cardiomyopathy. 61
31730522 2019
26
Exosome Treatment Enhances Anti-Inflammatory M2 Macrophages and Reduces Inflammation-Induced Pyroptosis in Doxorubicin-Induced Cardiomyopathy. 61
31600901 2019
27
Astragaloside IV alleviates doxorubicin induced cardiomyopathy by inhibiting NADPH oxidase derived oxidative stress. 61
31229536 2019
28
SESN2 protects against doxorubicin-induced cardiomyopathy via rescuing mitophagy and improving mitochondrial function. 61
31199952 2019
29
Extracorporeal shock waves protect cardiomyocytes from doxorubicin-induced cardiomyopathy by upregulating survivin via the integrin-ILK-Akt-Sp1/p53 axis. 61
31434946 2019
30
Advantages of prophylactic versus conventionally scheduled heart failure therapy in an experimental model of doxorubicin-induced cardiomyopathy. 61
31324258 2019
31
Blockade of L-type Ca2+ channel attenuates doxorubicin-induced cardiomyopathy via suppression of CaMKII-NF-κB pathway. 61
31285514 2019
32
Synthesis of Isosteviol analogues as potential protective agents against Doxorubicin-induced cardiomyopathy in zebrafish embryos. 61
31129053 2019
33
Oroxylum indicum root bark extract prevents doxorubicin-induced cardiac damage by restoring redox balance. 61
29398409 2019
34
Doxorubicin-Induced Cardiomyopathy in Children. 61
31187890 2019
35
[Mitochondrial Antioxidant Plastomitin Improves Cardiac Function in Doxorubicin-Induced Cardiomyopathy]. 61
31242839 2019
36
Doxorubicin-induced cardiomyopathy associated with inhibition of autophagic degradation process and defects in mitochondrial respiration. 61
30765730 2019
37
Mesenchymal Stem Cell Therapy for Doxorubicin-Induced Cardiomyopathy: Potential Mechanisms, Governing Factors, and Implications of the Heart Stem Cell Debate. 61
31258475 2019
38
Cardiovascular variability and β-ARs gene expression at two stages of doxorubicin - Induced cardiomyopathy. 61
30342983 2019
39
Role of Endothelium in Doxorubicin-Induced Cardiomyopathy. 61
30623145 2018
40
PTEN inhibitor VO-OHpic attenuates inflammatory M1 macrophages and cardiac remodeling in doxorubicin-induced cardiomyopathy. 61
30095997 2018
41
Protective effect of miR378* on doxorubicin-induced cardiomyocyte injury via calumenin. 61
29665007 2018
42
Localized Doxorubicin-Induced Cardiomyopathy Complicated With Shower Emboli Originating From Apical Intramural Thrombi. 61
29459534 2018
43
Downregulation of miR-130a, antagonized doxorubicin-induced cardiotoxicity via increasing the PPARγ expression in mESCs-derived cardiac cells. 61
29988029 2018
44
A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish. 61
29939187 2018
45
Anti-oxidant effect of bergamot polyphenolic fraction counteracts doxorubicin-induced cardiomyopathy: Role of autophagy and c-kitposCD45negCD31neg cardiac stem cell activation. 61
29654879 2018
46
Expression Profiling of Human Pluripotent Stem Cell-Derived Cardiomyocytes Exposed to Doxorubicin-Integration and Visualization of Multi-Omics Data. 61
29385562 2018
47
Translational systems pharmacology-based predictive assessment of drug-induced cardiomyopathy. 61
29341478 2018
48
Embryonic stem cell-derived cardiomyocytes for the treatment of doxorubicin-induced cardiomyopathy. 61
29402309 2018
49
The Role of Autophagy in the Heart. 61
29068766 2018
50
Cutaneous Toxicity in a Laboratory Beagle (Canis lupus familiaris) after Chronic Administration of Doxorubicin Hydrochloride. 61
29460722 2018

Variations for Doxorubicin Induced Cardiomyopathy

Expression for Doxorubicin Induced Cardiomyopathy

Search GEO for disease gene expression data for Doxorubicin Induced Cardiomyopathy.

Pathways for Doxorubicin Induced Cardiomyopathy

Pathways related to Doxorubicin Induced Cardiomyopathy according to GeneCards Suite gene sharing:

(show all 34)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.59 MET MAPK14 HGF EPOR EPHB2 EGFR
2
Show member pathways
13.45 MET MAPK14 HGF GATA4 EPOR EPHB2
3
Show member pathways
13.36 MET MAPK14 HGF EPOR EPHB2 EGFR
4
Show member pathways
13.34 MET MAPK14 HGF EPOR EPHB2 EGFR
5
Show member pathways
13.2 MET MAPK14 HGF EPOR EPHB2 EGFR
6
Show member pathways
13.14 MET HGF EPOR EPHB2 EGFR
7
Show member pathways
13.05 MET MAPK14 HGF EPOR EPHB2 EGFR
8
Show member pathways
13.01 MET MAPK14 HGF EPOR EPHB2 EGFR
9
Show member pathways
12.85 MET MAPK14 HGF EPHB2 EGFR
10
Show member pathways
12.78 MET HGF EPOR EGFR CSF3
11
Show member pathways
12.74 MET MAPK14 EPOR EPHB2 EGFR
12
Show member pathways
12.72 MET MAPK14 HGF EGFR
13
Show member pathways
12.69 MAPK14 GATA4 EPOR EGFR
14 12.66 MET HGF EPOR EGFR
15 12.58 MET MAPK14 HGF EGFR
16
Show member pathways
12.49 MET MAPK14 HGF EGFR
17
Show member pathways
12.45 MET MAPK14 HGF EGFR CNR1
18 12.22 MET HGF EGFR
19 12.11 MET MAPK14 HGF EGFR
20 11.96 MET EPHB2 EGFR
21 11.9 MET HGF GATA4
22 11.89 MET HGF EGFR
23
Show member pathways
11.73 MET MAPK14 HGF EPOR EPHB2 EGFR
24
Show member pathways
11.7 MET HGF EGFR
25 11.35 MET HGF CSF3
26
Show member pathways
11.26 MET HGF EGFR
27 11.21 MET HGF EGFR
28 11.15 MET EGFR
29 11.08 MET HGF EGFR
30 11.07 EPOR EGFR
31 11.04 MAPK14 GATA4
32 10.84 MET HGF
33 10.81 MET HGF EGFR
34 10.07 MET HGF EPOR EPHB2 EGFR DES

GO Terms for Doxorubicin Induced Cardiomyopathy

Cellular components related to Doxorubicin Induced Cardiomyopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.17 MET MAPK14 HGF EPOR EPHB2 EGFR
2 receptor complex GO:0043235 9.13 MET EPHB2 EGFR

Biological processes related to Doxorubicin Induced Cardiomyopathy according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.02 MET MAPK14 EPOR EGFR CSF3 CNR1
2 protein phosphorylation GO:0006468 9.86 MET MAPK14 EPHB2 EGFR
3 positive regulation of transcription by RNA polymerase II GO:0045944 9.8 MET MAPK14 HGF GATA4 EGFR CSF3
4 MAPK cascade GO:0000165 9.71 MET MAPK14 HGF EGFR
5 peptidyl-tyrosine phosphorylation GO:0018108 9.7 MET EPHB2 EGFR
6 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.69 MET EPHB2 EGFR
7 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.65 HGF EPOR CSF3
8 cell morphogenesis GO:0000902 9.63 MAPK14 HGF EPHB2
9 liver development GO:0001889 9.61 MET HGF EGFR
10 axonal fasciculation GO:0007413 9.54 EPHB2 CNR1
11 positive regulation of kinase activity GO:0033674 9.54 MET EPHB2 EGFR
12 hepatocyte growth factor receptor signaling pathway GO:0048012 9.49 MET HGF
13 learning or memory GO:0007611 9.43 EPHB2 EGFR CNR1
14 negative regulation of autophagy GO:0010507 9.33 MET HGF GATA4
15 negative regulation of hydrogen peroxide-mediated programmed cell death GO:1901299 8.96 MET HGF
16 positive regulation of protein kinase B signaling GO:0051897 8.92 MET HGF EGFR CSF3

Molecular functions related to Doxorubicin Induced Cardiomyopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase activity GO:0004672 9.67 MET MAPK14 EPHB2 EGFR
2 protein tyrosine kinase activity GO:0004713 9.5 MET EPHB2 EGFR
3 protein phosphatase binding GO:0019903 9.43 MET MAPK14 EGFR
4 identical protein binding GO:0042802 9.17 MET HGF EPOR EPHB2 EGFR DES
5 NFAT protein binding GO:0051525 9.16 MAPK14 GATA4
6 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.13 MET EPHB2 EGFR

Sources for Doxorubicin Induced Cardiomyopathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....